Crinetics Pharmaceuticals Conference Call Summary Company Overview - **Company**: Crinetics Pharmaceuticals (NasdaqGS:CRNX) - **Date**: January 05, 2026 - **Key Products**: Palsonify (for acromegaly), Atumelnant (for congenital adrenal hyperplasia, CAH) Key Points Industry and Market Context - The call discussed the acromegaly market, highlighting approximately **36,000 people** living with the condition in the U.S. [7] - The company aims to address the challenges faced by patients with acromegaly, many of whom have been stalled by inconsistent treatments [7] Product Launch and Performance - **Palsonify**: - Launched successfully in Q4 2025, with over **200 enrollment forms** processed [12] - Achieved **$5 million** in unaudited net revenue for the fourth quarter [12] - The launch strategy focuses on engaging both actively managed patients and those who have not been diagnosed [9] - Positive patient feedback has been reported, with many switching from injectable therapies to Palsonify [10] - **Atumelnant**: - Positioned to transform CAH treatment, aiming to provide a new standard of care without the side effects of high-dose steroids [5] - Data indicates a robust benefit-risk profile, with ongoing phase three studies planned [6] - The drug is designed to selectively block the ACTH receptor, potentially leading to significant reductions in adrenal androgens [17] Clinical Data and Studies - **Atumelnant Phase 2 Study**: - Cohort four results showed sustained reductions in androstenedione (A4) levels while tapering glucocorticoids [22] - A4 reductions were observed even with glucocorticoid doses reduced to physiological levels [24] - The study demonstrated a **67% reduction** in A4 levels in cohort four [33] - **Safety Profile**: - Atumelnant has been well tolerated with no serious adverse events reported across over **750 weeks** of patient exposure [30] - Common adverse events included headache and fatigue, typical for this patient population [29] Future Plans and Expectations - The company is optimistic about the upcoming **phase 3 CALM CAH study**, targeting **150 patients** to evaluate Atumelnant's safety and efficacy [30] - The study aims to demonstrate a statistically significant difference in achieving normal A4 levels while on physiological glucocorticoid doses [31] - Crinetics plans to continue expanding its pipeline, with additional candidates like paltusotine for carcinoid syndrome and CRN9682 for SST2-expressing cancers [36] Commercial Strategy - The company emphasizes commercial execution as a top priority, with a focus on building relationships with healthcare providers and payers [11] - Early formulary inclusions have been secured, and the company is actively engaging with payers to ensure patient access [12][70] Additional Insights - The company is committed to addressing the long diagnostic delays for acromegaly, which can take **5 to 10 years** [9] - The patient ambassador program aims to leverage patient experiences to enhance awareness and support for Palsonify [13] Conclusion Crinetics Pharmaceuticals is positioned for growth in the endocrine treatment market, with successful product launches and promising clinical data for Atumelnant. The company is focused on improving patient outcomes and expanding its market presence through strategic commercial initiatives and ongoing clinical studies.

Core Insights - Crinetics Pharmaceuticals reported unaudited and preliminary net product revenue of over $5 million for PALSONIFY in the fourth quarter of 2025, with over 200 enrollment forms submitted by the end of December [2][4][5] - Positive topline results from the fourth cohort of the Phase 2 congenital adrenal hyperplasia (CAH) study of atumelnant were announced, showing a 67% mean reduction in androstenedione levels and enabling 88% of participants to successfully reduce glucocorticoid doses to physiological levels [1][8][9] Company Performance - The launch of PALSONIFY, approved by the FDA on September 25, 2025, has been characterized by strong execution, with over 200 enrollment forms and a broad prescriber base [3][4][7] - Feedback from patients, physicians, and payers has been positive, leading to early formulary inclusions by payers [4][5] Clinical Study Results - The fourth cohort of the Phase 2 TouCAHn trial involved 10 patients with classic CAH, with treatment resulting in significant reductions in androstenedione levels [5][8] - Atumelnant was well-tolerated, with no serious adverse events reported, and a favorable benefit/risk profile maintained throughout the study [11][14] Future Outlook - Crinetics plans to host an investor conference call to discuss the topline results from the study, indicating ongoing engagement with investors and stakeholders [15][16] - Atumelnant is positioned as a potential transformational treatment for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, with ongoing Phase 3 clinical development [17][20]

Group 1 - Crinetics Pharmaceuticals will host a conference call and webcast on January 5, 2026, to provide updates on PALSONIFY™ commercialization and disclose topline results from the Phase 2 trial of atumelnant [1][2] - PALSONIFY™ (paltusotine) is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Crinetics has a deep pipeline of over 10 disclosed programs, including atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors [4] Group 2 - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies targeting G-protein coupled receptors (GPCRs) with tailored pharmacology [3]

Core Insights - Crinetics Pharmaceuticals, Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, at 9:45 a.m. Pacific Time [1] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors through patient-centered science [3] - The company specializes in discovering, developing, and commercializing novel therapies, particularly targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - Crinetics' lead product, PALSONIFY™ (paltusotine), is the first once-daily oral treatment approved by the U.S. FDA for adults with acromegaly who have had an inadequate response to surgery or for whom surgery is not an option [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors [4] - The company has a deep pipeline of over 10 disclosed programs, including late-stage candidates such as atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome, and CRN09682 for treating SST2 expressing neuroendocrine tumors and other solid tumors [4] - Additional discovery programs target various endocrine conditions, including neuroendocrine tumors, Graves' disease, polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications [4]

Core Insights - Crinetics Pharmaceuticals has initiated the CALM-CAH Phase 3 trial for atumelnant, a novel oral ACTH receptor antagonist aimed at treating classic congenital adrenal hyperplasia (CAH) [1][2] - The trial will assess atumelnant's effectiveness in normalizing adrenal androgen levels and reducing glucocorticoid levels to physiological ranges, setting a new standard for disease control assessment [2][3] - Atumelnant is the first small molecule ACTH receptor antagonist in late-stage clinical development, showing promising results in a Phase 2 study with significant reductions in key biomarkers [2][4] Company Overview - Crinetics Pharmaceuticals focuses on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and innovative therapies [5] - The company has a robust pipeline, including its lead product PALSONIFY™ for acromegaly and atumelnant for CAH and ACTH-dependent Cushing's syndrome [6][7] - Crinetics has received Orphan Drug Designation from the FDA for atumelnant, highlighting its potential impact on rare diseases [3]

Core Viewpoint - Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) is recognized by Wall Street analysts as a promising biotech stock, with expectations for significant growth in 2026 due to the launch of key drugs [1][2]. Group 1: Company Overview - Crinetics Pharmaceuticals is a clinical-stage drug company focused on developing oral treatments for rare endocrine diseases and tumors, including acromegaly, Cushing's disease, carcinoid syndrome, and congenital adrenal hyperplasia (CAH) [5]. - The company utilizes small molecules and peptide agonists that target hormone receptors in its drug development efforts [5]. Group 2: Pipeline and Research - The company is currently conducting the BRAVESST2 study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, a drug developed from its nonpeptide drug conjugate (NDC) platform [3]. - The first patient has been dosed in Phase ½ of the study evaluating CRN09682 in patients with metastatic or locally advanced somatostatin receptor type 2 (SST2)-positive neuroendocrine tumors [2]. Group 3: Financial Position - Crinetics is in a strong financial position, with more cash than debt on its balance sheet, which allows the company to accelerate its pipeline development [3]. Group 4: Leadership Insight - Stephen Betz, Chief Scientific Officer and Co-Founder of Crinetics, emphasized that CRN09682 was developed to meet the need for a more efficacious, safer, and convenient targeted therapy for patients with SST2-expressing tumors [4].

Core Insights - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan, totaling 39,575 shares in stock options and 26,525 RSUs [1][2] Company Overview - Crinetics Pharmaceuticals is a global pharmaceutical company focused on transforming the treatment of endocrine diseases and related tumors, emphasizing patient needs and targeting G-protein coupled receptors (GPCRs) with small molecules [3] Product Pipeline - The lead product, PALSONIFY™ (paltusotine), is the first oral treatment approved by the U.S. FDA for adults with acromegaly who have not responded adequately to surgery [4] - Paltusotine is also in clinical development for carcinoid syndrome associated with neuroendocrine tumors, with a pipeline that includes over 10 disclosed programs targeting various endocrine conditions [4]

Core Insights - Crinetics Pharmaceuticals has initiated a Phase 1/2 clinical trial for CRN09682, targeting SST2-positive neuroendocrine tumors and other solid tumors, marking a significant milestone for the company's nonpeptide drug conjugate platform [1][2] Company Overview - Crinetics Pharmaceuticals is focused on transforming the treatment of endocrine diseases and related tumors, leveraging expertise in G-protein coupled receptors (GPCRs) and small molecule design [5] - The company has a deep pipeline of over 10 disclosed programs, including PALSONIFY™ (paltusotine), which is the first oral treatment approved by the U.S. FDA for acromegaly [6][7] Drug Development - CRN09682 is a first-in-class, non-radioactive, nonpeptide drug conjugate designed to selectively bind to SST2-expressing tumor cells, releasing a potent cytotoxic agent, monomethyl auristatin E (MMAE), directly within the tumor [4] - The Phase 1/2 BRAVESST2 trial will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CRN09682, with up to 150 participants expected to be enrolled [3] Clinical Trial Details - The trial consists of a dose-escalation study to determine the maximum tolerated dose and a dose expansion phase to further evaluate CRN09682 in selected SST2-expressing tumor types [3] - Eligible patients must have metastatic or locally advanced disease progression following standard therapies, confirmed by somatostatin receptor imaging [3]

Core Insights - MPM BioImpact fully exited its position in Crinetics Pharmaceuticals, selling 428,975 shares for approximately $12.3 million, which represented 2.1% of its assets under management in the previous quarter [1][2][7] - Crinetics Pharmaceuticals has experienced a significant decline in stock price, down 19% over the past year, while the S&P 500 has increased by 13% during the same period [3] - The company reported a net loss of $130.1 million for the third quarter, despite generating $143,000 in revenue from a licensing agreement for its lead candidate, Paltusotine [9] Company Overview - Crinetics Pharmaceuticals is a clinical-stage biotechnology company focused on developing oral therapies for rare endocrine diseases and related tumors, with Paltusotine targeting acromegaly and neuroendocrine tumors [5] - The company's market capitalization is $4.4 billion, with a trailing twelve-month (TTM) revenue of $1.5 million and a TTM net income loss of $423.1 million [4] Recent Developments - The FDA approved Palsonify on September 25, 2025, marking a significant transition for Crinetics from a clinical-stage to a commercial-stage company [6][9] - The company has a cash reserve of $1.1 billion as of September 30, 2023, which supports its operations into 2029 [9] - The exit by MPM BioImpact may indicate a shift in risk tolerance or a search for better investment opportunities, particularly as Crinetics navigates its commercial launch [6]

Core Insights - Crinetics Pharmaceuticals has initiated the pivotal Phase 3 CAREFNDR trial to evaluate the efficacy and safety of paltusotine for treating carcinoid syndrome associated with neuroendocrine tumors, building on positive Phase 2 results [1][2][3] Company Overview - Crinetics Pharmaceuticals is focused on developing transformative therapies for endocrine diseases and related tumors, with a core expertise in targeting G-protein coupled receptors [7][8] - The company’s lead product, paltusotine, is the first once-daily oral treatment approved for adults with acromegaly who have had an inadequate response to surgery [8] Clinical Trial Details - The CAREFNDR trial will enroll 141 adults with carcinoid syndrome, randomizing participants in a 2:1 ratio to receive either paltusotine 80 mg or a matching placebo [2] - The primary endpoint of the trial is to measure the change in flushing episodes per day from baseline to Week 12, with bowel movement frequency as a key secondary endpoint [2] - Following the 16-week randomized period, the trial includes a 104-week open-label extension to evaluate long-term efficacy and safety [2] Product Information - Paltusotine is a selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide currently in Phase 3 development for carcinoid syndrome, showing rapid and sustained reductions in symptoms during Phase 2 trials [5][6] - Approximately 20% of patients with neuroendocrine tumors experience carcinoid syndrome, characterized by symptoms such as diarrhea and flushing [6] Future Development - Crinetics is also exploring additional treatment options for neuroendocrine tumors through CRN09682, an investigational anti-tumor candidate that has received Investigational New Drug clearance [3]